©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
The Amino Acid at the X Position of an Asn-X-Ser Sequon Is an Important Determinant of N-Linked Core-glycosylation Efficiency (*)

(Received for publication, November 8, 1995; and in revised form, December 28, 1995)

Susan H. Shakin-Eshleman (1)(§) Steven L. Spitalnik (2) Lakshmi Kasturi (1)

From the  (1)Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106 and the (2)University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

N-Linked glycosylation is a common form of protein processing that can profoundly affect protein expression, structure, and function. N-Linked glycosylation generally occurs at the sequon Asn-X-Ser/Thr, where X is any amino acid except Pro. To assess the impact of the X amino acid on core glycosylation, rabies virus glycoprotein variants were generated by site-directed mutagenesis with each of the 20 common amino acids substituted at the X position of an Asn-X-Ser sequon. The efficiency of core glycosylation at the sequon in each variant was quantified in a rabbit reticulocyte lysate cell-free translation system supplemented with canine pancreas microsomes. The presence of Pro at the X position completely blocked core glycosylation, whereas Trp, Asp, Glu, and Leu were associated with inefficient core glycosylation. The other variants were more efficiently glycosylated, and several were fully glycosylated. These findings demonstrate that the X amino acid is an important determinant of N-linked core-glycosylation efficiency.


INTRODUCTION

One of the most common types of protein modification is N-linked glycosylation, in which oligosaccharides are added to specific Asn residues(1, 2) . N-Linked glycosylation plays a critical role in the expression of most cell-surface and secreted proteins and is often required for protein stability, antigenicity, and biological function(1, 3, 4, 5, 6) . The effects of N-linked glycosylation often depend on the number and position of N-linked oligosaccharides added to a protein chain(5, 7, 8, 9, 10, 11) . This is determined during core glycosylation, in which the oligosaccharide Glc(3)Man(9)GlcNAc(2) is transferred to a protein by the enzyme oligosaccharyltransferase(2, 12, 13) . Oligosaccharyltransferase is integral to the endoplasmic reticulum membrane, and the active site of the enzyme resides near the endoplasmic reticulum membrane on the lumenal side(13, 14, 15) . Core glycosylation usually occurs co-translationally as the glycosylation site on a nascent protein enters the endoplasmic reticulum lumen(14, 16, 17, 18) .

Despite the importance of N-linked glycosylation, little is known about the protein signals that control the efficiency of oligosaccharide addition at specific Asn residues. N-Linked glycosylation generally occurs at the sequon Asn-X-Ser or Asn-X-Thr, where X is any amino acid except proline (Asn-X-Ser/Thr)(15, 19, 20) . However, because many Asn-X-Ser/Thr sequons in proteins are glycosylated inefficiently(8, 21, 22, 23, 24, 25, 26) or not at all(20, 27, 28) , other protein signals must also control this process.

We have used rabies virus glycoprotein (RGP) (^1)as a model system to study the regulation of N-linked core glycosylation(8, 29, 30) . Using a rabbit reticulocyte lysate cell-free translation system supplemented with canine pancreas microsomes, we can examine the effects of specific amino acid substitutions on the core-glycosylation efficiency (CGE) of individual sequons in RGP(29) . Our results in the cell-free system are similar to those obtained when RGP variants are expressed in transfected Chinese hamster ovary cells(8, 29) . In this report we examine the impact of the X amino acid on CGE. To do this we generated a set of RGP variants by site-directed mutagenesis in which each of the 20 common amino acids was substituted at the X position of the sequon Asn-Leu-Ser. We then quantified the CGE at the sequon in each variant using the cell-free system described. Our results demonstrate that the amino acid at the X position is an important determinant of CGE.


MATERIALS AND METHODS

Construction of a Cloning Vector for Cassette Mutagenesis

A cloning vector for cassette mutagenesis was generated from the plasmid that encodes RGP(1- -) by the introduction of unique EcoRV and SacI restriction sites on either side of the sequon (Fig. 2). This was accomplished using the polymerase chain reaction-based method, splicing by overlap extension(31) , essentially as described(8) . Briefly, polymerase chain reaction amplification of RGP cDNA was performed with two separate primer pairs to generate overlapping cDNA fragments containing EcoRV and SacI restriction sites. The mutagenic primers used for these amplification reactions were: 5`-ggatatcactgcagagagctcAAAGTTGGATACATCTTAGC-3` (sense primer) and 3`-GGTTTGTTAAACCATCACCTCCTatagtgacgtctctcgag-5` (antisense primer). The regions corresponding to the RGP sequence are shown in capital letters, and the EcoRV and SacI sites in the primer tails are underlined. Those cDNA fragments were combined in a third polymerase chain reaction. The resulting cDNA fragment was digested with HindIII and XhoI and ligated into the corresponding restriction sites in pRGP(1- -) to generate the plasmid pRGP(1- -)ES. In that plasmid, the cDNA encoding amino acids 32-46 of RGP(1- -) is replaced with a 20-base pair sequence containing the EcoRV and SacI restriction sites (Fig. 2, A and B). The polymerase chain reaction-derived HindIII-XhoI region of pRGP(1- -)ES was sequenced to confirm successful mutagenesis. This plasmid was digested with EcoRV and SacI restriction enzymes and gel-purified to generate a vector for oligonucleotide cassette mutagenesis at sequon 1 (Fig. 2C).


Figure 2: RGP variants with amino acid substitutions at the X position of sequon 1 were generated by oligonucleotide cassette mutagenesis. A, the DNA and amino acid sequences near sequon 1 in RGP(1- -) are shown; the sequon is underlined. B, a cloning vector for cassette mutagenesis, pRGP(1- -)ES, was generated from pRGP(1- -) by replacing the sequence for amino acids 32-46 with a novel sequence (uppercase letters) containing EcoRV and SacI restriction sites (underlined). C, for cassette mutagenesis the cloning vector was digested with EcoRV and SacI restriction enzymes. D, an oligonucleotide duplex was generated for cassette mutagenesis. The oligonucleotides in the duplex are complementary to one another except at the bases corresponding to the X amino acid in sequon 1 (XXX); both oligonucleotides are fully degenerate at that position. E, ligation of the duplex (uppercase letters) into the cloning vector (lowercase letters) restores the amino acid coding sequence of RGP(1- -), except at the position corresponding to the X amino acid in sequon 1 (underlined). At that position each plasmid encodes one of the 20 common amino acids.



Construction of Plasmids Encoding Variants of RGP(1- -) with Amino Acid Substitutions at the X Position of Sequon 1

A cassette mutagenesis approach was used to generate plasmids encoding variants of RGP(1- -) with amino acid substitutions at the X position of sequon 1. For this construction, sense and antisense oligonucleotides were synthesized, which were complementary to one another except at the nucleotide positions corresponding to the codon for amino acid 38 (Fig. 2D). To introduce the full spectrum of amino acid substitutions at that position, each oligonucleotide was completely degenerate at all three of the nucleotide positions. Those oligonucleotides were combined in 1 times ligation buffer (30 mM Tris-HCl, pH 7.8, 10 mM MgCl(2), 10 mM dithiothreitol, 5 mM ATP) at a final concentration of 100 µM each and hybridized to one another by heating to 68 °C for 5 min and cooling slowly to room temperature. The resulting oligonucleotide duplex was ligated into the RGP(1- -)ES cloning vector at the EcoRV and SacI sites. Each plasmid resulting from this ligation encodes a protein identical to RGP(1- -) except for the amino acid at the X position of sequon 1 (Fig. 2E). Ligated plasmids were transformed into competent Escherichia coli and isolated by alkaline lysis. DNA sequencing of each plasmid between the EcoRV and SacI sites was performed to identify the specific amino acid substitution in each recombinant plasmid. Plasmids containing 18 of the 20 common amino acids at position 38 were isolated using this approach. The remaining two plasmids, encoding Asp and Glu at position 38, were isolated using a similar approach using an oligonucleotide duplex with the sequence GA(A/T) at the codon corresponding to amino acid 38 (sense sequence).

In Vitro Transcription and Expression in the Cell-free System

RNA encoding RGP variants was generated by in vitro transcription with T7 RNA polymerase as described previously (8, 29) . In vitro translation was performed using a rabbit reticulocyte lysate system supplemented with [S]methionine and canine pancreas microsomes (Boehringer Mannheim) as described(29) , except that the amount of microsomes was reduced to 1 µl/15-µl translation reaction. Following translation the reactions were incubated on ice for 20 min in the presence of 200 µg/ml proteinase K and then for 5 min in the presence of 0.5 mg/ml phenylmethylsulfonyl fluoride. Samples were analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography as described(8) . Densitometric analysis of gel autoradiographs exposed in the linear range was performed using a Sci-Scan 5000 system (U. S. Biochemical Corp.).


RESULTS

Construction of Plasmids Encoding RGP Variants with Amino Acid Substitutions at Position 38

The variants used in this study were derived from RGP. Wild type RGP is a 505-amino acid type 1 transmembrane protein with a 439-amino acid extracellular domain and a 44-amino acid cytoplasmic tail (Fig. 1, RGP(WT))(32) . The extracellular domain has three sequons for N-linked glycosylation at Asn (sequon 1), Asn (sequon 2), and Asn (sequon 3)(32) . To study the core glycosylation of individual sequons in RGP, sequons 2 and 3 in RGP(WT) were deleted by site-directed mutagenesis by substituting Thr at each Asn-X-Thr sequon with Ala(8) . The resulting variant, RGP(1- -), contains a single glycosylation sequon with the sequence Asn-Leu-Ser (Fig. 1). Sequon 1 was selected for these studies since core glycosylation is normally inefficient at this site(8, 29, 30) . This is advantageous because the effects of amino acid substitutions near Asn can be detected whether they increase or decrease CGE.


Figure 1: Structure of RGP and RGP variants. The extracellular domain of RGP(WT) contains three sequons at Asn, Asn, and Asn. In RGP(1- -) the sequons at Asn and Asn were deleted by site-directed mutagenesis in which the Thr residue in each sequon was replaced with Ala. RGP(1- -) contains a single sequon with the sequence Asn-Leu-Ser (sequon 1). RGP(1- -)X38 variants were derived from RGP(1- -) by oligonucleotide cassette mutagenesis; each variant contains one of the 20 common amino acids at the X position of sequon 1. Black bar, sequon present; white bar, sequon deleted; stippled bar, transmembrane domain; hatched bar, cytoplasmic tail.



To simplify construction of RGP variants with amino acid substitutions at the X position of sequon 1, pRGP(1- -) was further modified to generate a cloning vector for cassette mutagenesis. This involved the introduction of unique EcoRV and SacI restriction sites on either side of sequon 1 ( Fig. 2and ``Materials and Methods''). An oligonucleotide cassette mutagenesis approach was used to generate a set of plasmids encoding variants of RGP(1- -) with each of the 20 common amino acids at the X position of sequon 1 (collectively referred to as RGP(1- -)X38 variants) ( Fig. 1and ``Materials and Methods''). A variant with Leu at position 38 (corresponding to the sequence normally present in RGP) was among the variants isolated using that approach. DNA sequencing was performed to confirm that each RGP(1- -)X38 plasmid encoded a protein identical to RGP(1- -) except for the amino acid at position 38.

Expression of RGP Variants in a Cell-free System

Each RGP variant was expressed in a rabbit reticulocyte cell-free translation system supplemented with [S]methionine and canine pancreas microsomes(33, 34, 35) . The microsomes cleave the signal sequence of these proteins and add core oligosaccharides(8, 30) . This cell-free system provides a highly reproducible method for quantifying the co-translational CGE of specific sequons in recombinant proteins(30) . Analysis of core glycosylation in this system is simpler than in intact cells because oligosaccharide processing is limited and protein variants can be analyzed without immunoprecipitation. Also, unlike analysis in intact cells, alterations in protein stability or expression resulting from amino acid substitutions are uncommon. Our previous studies have demonstrated that the core-glycosylation efficiencies of RGP variants in this system are similar to those observed when the same proteins are expressed in transfected Chinese hamster ovary cells(8, 29) .

RGP variants with each of the 20 common amino acids at the X position of sequon 1 were translated in parallel in the cell-free system described. Translation of the variants in the absence of microsomes confirmed that the amino acid substitutions at the X position did not alter the electrophoretic migration of the proteins (data not shown). The variants were then translated in the presence of microsomes to examine the effect of the X amino acid on core glycosylation. The amount of microsomes added to each reaction was optimized to maximize incorporation of RGP into microsomes while maintaining adequate translational activity. Under these conditions each translation reaction contains a small amount of protein that is not targeted to microsomes(8, 30) . These untargeted proteins are not glycosylated, retain the 19-amino acid N-terminal signal sequence, and migrate between the nonglycosylated and glycosylated forms of RGP synthesized on microsomes in our gel system(8, 30) . Because these untargeted proteins can interfere with the quantification of CGE, they were removed from translation reactions by proteinase K digestion prior to gel analysis(36) . The extracellular domain of RGP variants is translocated into the microsomal lumen during protein synthesis where it is protected from proteinase K digestion. In contrast, the 44-amino acid cytoplasmic tail (Fig. 1) remains outside of the microsome and is removed by this treatment. Removal of the cytoplasmic tail produces a small shift in the electrophoretic mobility of RGP proteins (data not shown) but does not interfere with the quantification of CGE. Following proteinase K treatment, radiolabeled translation products were analyzed directly (without immunoprecipitation) by gel electrophoresis and autoradiography. A gel autoradiograph showing the translation products of all 20 RGP variants is shown in Fig. 3. The positions of the nonglycosylated protein (N) and the protein glycosylated with a single core oligosaccharide (G) are shown. The total amount of protein produced in each translation can vary from tube to tube reflecting differences in the amount of RNA in each sample. For this reason glycosylation efficiency is determined by comparing the amounts of glycosylated and nonglycosylated protein produced in a single reaction for each variant.


Figure 3: Core glycosylation of RGP variants in the cell-free system. RNA encoding each RGP variant was generated by in vitro transcription and expressed in the cell-free system in the presence of canine pancreas microsomes and [S]methionine. Translation products were treated with proteinase K and analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. The amino acid at the X position of sequon 1 in each variant is indicated. The migration positions of the nonglycosylated protein (N) and the protein glycosylated with a single core oligosaccharide (G) are indicated.



To quantify the CGE at the sequon in each RGP variant, the variants were expressed in the cell-free system in three independent experiments and autoradiographs from each experiment were analyzed by densitometric scanning. The densities of bands representing glycosylated (G) and nonglycosylated (N) proteins were quantified for each variant, and the CGE was calculated as follows: G/(N + G) times 100%(30) . The mean CGE ± 1 S.D. was then determined for each variant (Fig. 4). This analysis revealed that the CGE observed for each RGP variant was highly reproducible in this system.


Figure 4: CGE of RGP variants with amino acid substitutions at the X position of sequon 1. The 20 RGP variants generated by cassette mutagenesis were analyzed in the cell-free system as described for Fig. 3in three independent experiments. Gel autoradiographs from each experiment were exposed in the linear range and analyzed by densitometric scanning. The CGE of each variant was calculated as described in the text for each experiment, and the mean CGE ± 1 S.D. from the three experiments was determined (shown).



The experiments presented demonstrate that the amino acid at the X position of an Asn-X-Ser sequon can have a profound effect on CGE. These studies confirm that the presence of Pro at the X position completely blocks glycosylation(15, 20, 27, 37) . Also, consistent with our findings from earlier studies(8, 29, 30) , these data demonstrate that the sequon Asn-Leu-Ser is glycosylated at an intermediate level (mean CGE = 43%). Remarkably, we find that substitution of Leu with Trp, Asp, or Glu dramatically reduces the efficiency of core glycosylation (mean CGE = 5, 19, and 24%, respectively), whereas substitution of Leu with other amino acids increases CGE to varying degrees (mean CGE ranges from Phe = 70% to Ser = 97%). These results provide the first direct demonstration that amino acids at the X position of an Asn-X-Ser/Thr sequon can influence the efficiency of co-translational core glycosylation.


DISCUSSION

This report extends previous studies by providing the first comprehensive direct analysis of the impact of the X amino acids on CGE. We demonstrate that the CGE at an Asn-X-Ser sequon in RGP ranges from no glycosylation to full glycosylation, depending on which amino acid is present at the X position. This demonstrates that the X amino acid is an important determinant of CGE.

Because the structure and enzymatic mechanism of oligosaccharyltransferase are not well characterized, currently it is not possible to determine the mechanism by which individual amino acids influence core glycosylation. Several studies suggest that the spatial relationship of the Asn and Ser/Thr residues in a sequon may be critical for oligosaccharide transfer(37, 38, 39, 40, 41, 42, 43) . Large hydrophobic amino acids (e.g. Trp, Leu, Phe, and Tyr) may inhibit core glycosylation by producing an unfavorable local protein conformation. In contrast, Gly, which is small and does not constrain protein conformation, is associated with efficient core glycosylation. Other factors also appear to be important. The negatively charged amino acids (Asp and Glu) inhibit glycosylation, whereas the positively charged amino acids (Lys, Arg, and His) are favorable. The charge of the X amino acid may influence the ability of oligosaccharyltransferase to bind simultaneously to the sequon and the negatively charged dolichol-PP-oligosaccharide precursor(41, 44) . Interestingly, the X amino acids with hydroxy groups (Ser and Thr) and Cys are associated with highly efficient core glycosylation, whereas those with amide groups (Asn and Gln) are associated with suboptimal core glycosylation. Further characterization of oligosaccharyltransferase may help clarify the role that individual amino acids play in oligosaccharide addition.

The general nature of these findings is supported by studies comparing the X amino acid in glycosylated and nonglycosylated sequons in native glycoproteins. Those studies reveal that Cys, Trp (15) , Asp(19) , and Glu (27) are uncommon at the X position in core-glycosylated sequons. Studies of synthetic peptides in membrane preparations also find an inhibitory effect of Asp at the X position(41, 44) . The current report provides direct confirmation that Trp, Asp, and Glu at the X position inhibit core glycosylation. Interestingly, the sequon Asn-Cys-Ser in RGP is fully core-glycosylated. The lack of core glycosylation at Asn-Cys-Ser/Thr sequons in other proteins may reflect the potential of certain Cys residues to participate in disulfide bonding(40, 45) .

It is important to note that factors other than the X amino acid also influence core glycosylation. For example, the presence of Pro immediately following a sequon can inhibit core glycosylation(20, 37) , and the presence of Thr rather than Ser at the hydroxy position favors efficient glycosylation(15, 29, 42) . Our previous studies demonstrate that the inhibitory effect of Leu in the sequon Asn-Leu-Ser in RGP can be overcome by replacing Ser with Thr(29) . Studies are currently under way to compare the impact of other X amino acids in Asn-X-Thr versus Asn-X-Ser sequons. Core glycosylation can also be influenced by factors that influence the accessibility of a sequon to oligosaccharyltransferase, such as the position of the sequon in a protein(14, 20, 30, 46, 47) and the folding of the nascent protein chain(45, 48) . Core glycosylation is clearly a complex process influenced by a variety of factors. Further characterization of the protein signals that regulate core glycosylation will enhance our understanding of glycoprotein expression and facilitate the design of novel recombinant glycoproteins for research and clinical applications.


FOOTNOTES

*
This work was supported in part by funds from the National Blood Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Inst. of Pathology, Case Western Reserve University, School of Medicine, 2085 Adelbert Rd., Cleveland, OH 44106. Tel.: 216-844-8006; Fax: 216-844-1810.

(^1)
The abbreviations used are: RGP, rabies virus glycoprotein; CGE, core-glycosylation efficiency.


ACKNOWLEDGEMENTS

We thank Joyce Jentoft and James Eshleman for helpful discussions.


REFERENCES

  1. Varki, A. (1993) Glycobiology 3, 97-130 [Abstract]
  2. Kornfeld, R., and Kornfeld, S. (1985) Annu. Rev. Biochem. 54, 631-664 [CrossRef][Medline] [Order article via Infotrieve]
  3. West, C. M. (1986) Mol. Cell. Biochem. 72, 3-20 [Medline] [Order article via Infotrieve]
  4. Rademacher, T. W., and Dwek, R. A. (1989) in Carbohydrate Recognition in Cellular Function (Bock, G., and Harnett, S., eds) pp. 241-256, John Wiley & Sons Ltd., Chichester, W. Sussex, UK
  5. Shakin-Eshleman, S. H., and Spitalnik, S. L. (1993) Trends Glycosci. Glycotechnol. 5, 355-368
  6. Opdenakker, G., Rudd, P. M., Ponting, C. P., and Dwek, R. A. (1993) FASEB J. 7, 1330-1337 [Abstract/Free Full Text]
  7. Gallagher, P., Henneberry, J., Wilson, I., Sambrook, J., and Gething, M.-J. (1988) J. Cell Biol. 107, 2059-2073 [Abstract]
  8. Shakin-Eshleman, S. H., Remaley, A. T., Eshleman, J. R., Wunner, W. H., and Spitalnik, S. L. (1992) J. Biol. Chem. 267, 10690-10698 [Abstract/Free Full Text]
  9. Machamer, C. E., and Rose, J. K. (1988) J. Biol. Chem. 263, 5948-5954 [Abstract/Free Full Text]
  10. Roberts, P. C., Garten, W., and Klenk, H.-D. (1993) J. Virol. 67, 3048-3060 [Abstract]
  11. Omura, H., Otsu, M., Yoshimori, T., Tashiro, Y., and Kikuchi, M. (1992) Eur. J. Biochem. 210, 591-599 [Abstract]
  12. Hubbard, S. C., and Ivatt, R. J. (1981) Annu. Rev. Biochem. 50, 555-583 [CrossRef][Medline] [Order article via Infotrieve]
  13. Kelleher, D. J., Kreibich, G., and Gilmore, R. (1992) Cell 69, 55-65 [Medline] [Order article via Infotrieve]
  14. Nilsson, I. M., and von Heijne, G. (1993) J. Biol. Chem. 268, 5798-5801 [Abstract/Free Full Text]
  15. Kaplan, H. A., Welply, J. K., and Lennarz, W. J. (1987) Biochim. Biophys. Acta 906, 161-173 [Medline] [Order article via Infotrieve]
  16. Bergman, L. W., and Kuehl, W. M. (1977) Biochemistry 16, 4490-4497 [Medline] [Order article via Infotrieve]
  17. Rothman, J. E., and Lodish, H. F. (1977) Nature 269, 775-780 [Medline] [Order article via Infotrieve]
  18. Glabe, C. G., Hanover, J. A., and Lennarz, W. J. (1980) J. Biol. Chem. 255, 9236-9242 [Free Full Text]
  19. Marshall, R. D. (1974) Biochem. Soc. Symp. 40, 17-26 [Medline] [Order article via Infotrieve]
  20. Gavel, Y., and von Heijne, G. (1990) Protein Eng. 3, 433-442 [Abstract]
  21. Plummer, T. H., and Hirs, C. H. W. (1964) J. Biol. Chem. 239, 2530-2538 [Free Full Text]
  22. Pohl, G., Kallstrom, M., Bergsdorf, N., Wallen, P., and Jornvall, H. (1984) Biochemistry 23, 3701-3707 [Medline] [Order article via Infotrieve]
  23. Thim, L., Bjoern, S., Christensen, M., Nicolaisen, E. M., Lund-Hansen, T., Pedersen, A. H., and Hedner, U. (1988) Biochemistry 27, 7785-7793 [Medline] [Order article via Infotrieve]
  24. Stevenson, S. C., Wang, S., Deng, L., and Tall, A. R. (1993) Biochemistry 32, 5122-5126
  25. Curling, E. M. A., Hayter, P. M., Baines, A. J., Bull, A. T., Gull, K., Strange, P. G., and Jenkins, N. (1990) Biochem. J. 272, 333-337 [Medline] [Order article via Infotrieve]
  26. Inouye, S., Guo, Y., Ling, N., and Shimasaki, S. (1991) Biochem. Biophys. Res. Commun. 179, 352-358 [Medline] [Order article via Infotrieve]
  27. Mononen, I., and Karjalainen, E. (1984) Biochim. Biophys. Acta 788, 364-367
  28. Nakai, K., and Kanehisa, M. (1988) J. Biochem. (Tokyo) 104, 693-699
  29. Kasturi, L., Eshleman, J. R., Wunner, W. H., and Shakin-Eshleman, S. H. (1995) J. Biol. Chem. 270, 14756-14761 [Abstract/Free Full Text]
  30. Shakin-Eshleman, S. H., Wunner, W. H., and Spitalnik, S. L. (1993) Biochemistry 32, 9465-9472 [Medline] [Order article via Infotrieve]
  31. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59
  32. Wunner, W. H., Larson, J. K., Dietzschold, B., and Smith, C. L. (1988) Rev. Infect. Dis. 10, Suppl. 4, 771-784
  33. Pelham, H. R. B., and Jackson, R. J. (1976) Eur. J. Biochem. 67, 247-256 [Abstract]
  34. Scheele, G. (1983) Methods Enzymol. 96, 94-111 [Medline] [Order article via Infotrieve]
  35. Jackson, R. J., and Hunt, T. (1983) Methods Enzymol. 96, 50-74 [Medline] [Order article via Infotrieve]
  36. Perara, E., and Lingappa, V. R. (1985) J. Cell Biol. 101, 2292-2301 [Abstract]
  37. Bause, E. (1983) Biochem. J. 209, 331-336 [Medline] [Order article via Infotrieve]
  38. Beeley, J. G. (1977) Biochem. Biophys. Res. Commun. 76, 1051-1055 [Medline] [Order article via Infotrieve]
  39. Aubert, J.-P., Helbecque, N., and Loucheux-Lefebvre, M.-H. (1981) Arch. Biochem. Biophys. 208, 20-29 [Medline] [Order article via Infotrieve]
  40. Bause, E., Hettkamp, H., and Legler, G. (1982) Biochem. J. 203, 761-768 [Medline] [Order article via Infotrieve]
  41. Imperiali, B., and Shannon, K. L. (1991) Biochemistry 30, 4374-4380 [Medline] [Order article via Infotrieve]
  42. Bause, E., and Legler, G. (1981) Biochem. J. 195, 639-644 [Medline] [Order article via Infotrieve]
  43. Imperiali, B., Shannon, K. L., Unno, M., and Rickert, K. W. (1992) J. Am. Chem. Soc. 114, 7944-7945
  44. Bause, E., and Hettkamp, H. (1979) FEBS Lett. 108, 341-344 [CrossRef][Medline] [Order article via Infotrieve]
  45. Bulleid, N. J., Bassel-Duby, R. S., Freedman, R. B., Sambrook, J. F., and Gething, M. J. (1992) Biochem. J. 286, 275-280 [Medline] [Order article via Infotrieve]
  46. Livi, G. P., Lillquist, J. S., Miles, L. M., Ferrara, A., Sathe, G. M., Simon, P. L., Meyers, C. A., Gorman, J. A., and Young, P. R. (1991) J. Biol. Chem. 266, 15348-15355 [Abstract/Free Full Text]
  47. Landolt-Marticorena, C., and Reithmeier, R. A. F. (1994) Biochem. J. 302, 253-260 [Medline] [Order article via Infotrieve]
  48. Allen, S., Naim, H. Y., and Bulleid, N. J. (1995) J. Biol. Chem. 270, 4797-4804 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.